Home › Funds › SILVERCREST ASSET MANAGEMENT GROUP LLC › ABT

SILVERCREST ASSET MANAGEMENT GROUP LLC position in ABT

ABBOTT LABORATORIES · Health Care

SILVERCREST ASSET MANAGEMENT GROUP LLC reported holding 940,395 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$85.3M, representing 0.56% of its reported portfolio and ranking #40 among its reported holdings. SILVERCREST ASSET MANAGEMENT GROUP LLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)940.39K sh
Reported value held$85.33M
Portfolio Weight0.56%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SILVERCREST ASSET MANAGEMENT GROUP LLC's ABT position evolved

SILVERCREST ASSET MANAGEMENT GROUP LLC first disclosed a stake in ABT in Q3 2023 at 1,377,749 shares (US$133.4M). The position peaked in Q1 2025 at 1,243,548 shares, worth US$165.0M. Across 12 filings, SILVERCREST ASSET MANAGEMENT GROUP LLC increased the stake 1 time(s), trimmed it 10 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 940,395 shares valued at US$85.3M — a reduction of -154,205 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.38M $133.44M New
Q4 2023 1.31M $144.72M Reduce
Q1 2024 1.27M $144.70M Reduce
Q2 2024 1.24M $128.64M Reduce
Q3 2024 1.21M $137.82M Reduce
Q4 2024 1.28M $144.91M Add
Q1 2025 1.24M $164.96M Reduce
Q2 2025 1.21M $164.58M Reduce
Q3 2025 1.17M $156.65M Reduce
Q4 2025 1.12M $140.57M Reduce
Q1 2026 1.09M $112.38M Reduce
Q2 2026 940.39K $85.33M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has SILVERCREST ASSET MANAGEMENT GROUP LLC held ABT?

SILVERCREST ASSET MANAGEMENT GROUP LLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is SILVERCREST ASSET MANAGEMENT GROUP LLC's current position in ABT?

As of Q2 2026, SILVERCREST ASSET MANAGEMENT GROUP LLC holds 940.39K shares of ABT (ABBOTT LABORATORIES), valued at $85.33M, representing 0.56% of its reported portfolio and ranking #40.

Has SILVERCREST ASSET MANAGEMENT GROUP LLC been buying or selling ABT?

In the latest 13F filing (Q2 2026), SILVERCREST ASSET MANAGEMENT GROUP LLC reduced its position in ABT. The position peaked in Q1 2025 at 1.24M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.